Trials / Terminated
TerminatedNCT00162071
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
"A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | apadenoson |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2006-03-01
- First posted
- 2005-09-13
- Last updated
- 2017-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00162071. Inclusion in this directory is not an endorsement.